Tin tức & Cập nhật

The phase II CONFIDENCE* trial shows the benefit of dual therapy with the selective ns-MRA** finerenone and the SGLT2i** empagliflozin vs either agent alone in individuals with chronic kidney disease (CKD) and type 2 diabetes (T2D).

In patients with chronic kidney disease and type 2 diabetes who have not been previously treated with any mineralocorticoid receptor antagonist (MRA), the use of finerenone results in marked reductions in albuminuria, reports a study presented at ERA 2025.

A study presented at ESPGHAN 2025 reports that schoolchildren who consume energy drinks have unhealthier lifestyles and a different cardiovascular risk profile than their counterparts who do not or rarely consume energy drinks.